Pro Research Wall Street delves into biopharmaceutical leader - Investing.com India
| MKKGY Stock | USD 29.90 0.04 0.13% |
Slightly above 62% of Merck KGaA's investor base is looking to short. The analysis of overall sentiment of trading Merck KGaA ADR pink sheet suggests that many investors are alarmed at this time. Merck KGaA's investing sentiment can be driven by a variety of factors including economic data, Merck KGaA's earnings reports, geopolitical events, and overall market trends.
Merck |
Pro Research Wall Street delves into biopharmaceutical leader Investing.com India
Read at news.google.com
 |
Merck KGaA Fundamental Analysis
We analyze Merck KGaA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merck KGaA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merck KGaA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earnings To Growth
Price To Earnings To Growth Comparative Analysis
Merck KGaA is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Merck KGaA ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Merck KGaA pink sheet to make a market-neutral strategy. Peer analysis of Merck KGaA could also be used in its relative valuation, which is a method of valuing Merck KGaA by comparing valuation metrics with similar companies.
Peers
Merck KGaA Related Equities
| AKAN | Akanda Corp | 2.94 | ||||
| COLL | Collegium Pharmaceutical | 0.68 | ||||
| EOLS | Evolus | 0.80 | ||||
| INCR | INC Research | 1.48 | ||||
| ANIP | ANI Pharmaceuticals | 3.64 | ||||
| YCBD | CbdMD | 3.92 | ||||
| BFRI | Biofrontera | 9.09 |
Additional Tools for Merck Pink Sheet Analysis
When running Merck KGaA's price analysis, check to measure Merck KGaA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck KGaA is operating at the current time. Most of Merck KGaA's value examination focuses on studying past and present price action to predict the probability of Merck KGaA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck KGaA's price. Additionally, you may evaluate how the addition of Merck KGaA to your portfolios can decrease your overall portfolio volatility.